Status:

RECRUITING

Pharmacologic Augmentation of TMS for Depression With D-serine

Lead Sponsor:

Mclean Hospital

Conditions:

Depression

Eligibility:

All Genders

18-80 years

Phase:

PHASE1

Brief Summary

The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The i...

Detailed Description

Consent Process: After referral from the clinician, subjects will be contacted either by phone, by email, or in person, advised of the opportunity to participate in this study, and informed about wha...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of MDD
  • English-speaking
  • Adults aged 18-80
  • Must be able to swallow capsules
  • Relative contraindications/possible exclusion criteria:
  • Containing any implanted metal or devices
  • Current or previous seizure history
  • Active substance use that may significantly alter the seizure threshold
  • Any further safety clearances, and outpatient consultation opinions that are necessitated based on the answers to the screening will be obtained prior to moving forward with the study, as an already established practice within the clinic practice. In addition, any relative contraindications will be further reviewed according to Rossi et al.'s most updated safety guidelines for TMS.

Exclusion

  • Patients with pre-existing renal disease
  • Known allergy to D-serine, or with
  • Patients taking medications with known drug-drug interactions
  • Children
  • Pregnant or breast-feeding women
  • The investigators will not include children because prior safety and dosing studies excluded children. Although considered safe for TMS, the investigators will not include pregnant or breast-feeding women on the basis of unknown safety profile of exogenous D-serine for these patients.

Key Trial Info

Start Date :

April 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2026

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06876129

Start Date

April 1 2025

End Date

April 1 2026

Last Update

October 31 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

McLean Hospital

Belmont, Massachusetts, United States, 02478